Bayer's First US Pharma Plant Sits Between a $5B Stroke Drug and a $7.25B Roundup Tab

The trigger isn't growth — it's trade policy. A 100% Section 232 tariff on imported patented pharmaceuticals took effect on September 29, 2026 for any drugmaker not specifically named in Annex III of the April presidential proclamation. The Annex III list reads like a who's-who of branded pharma — AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi, GSK and Novo Nordisk among them — but Bayer isn't on it. That means every patented Bayer pill currently shipped into the US from its German and Finnish plants now faces a 100% duty, with the only escape hatch being a negotiated onshoring agreement that drops the rate to roughly 20%.

Pfizer carved out the template: under its January 2026 agreement with the Trump administration it committed $70B of US R&D and manufacturing spend in exchange for a three-year grace period exempting its products from the pharma tariff. Most of the rest of the industry followed with onshoring-style commitments — see the next section. Bayer is now joining that club from behind, and the Ohio plant is its negotiating chip: 600 permanent pharma jobs and 1,500 construction roles in a state where the governor and JobsOhio have been building a biomanufacturing workforce for the past 18 months.

Every major branded-pharma competitor is already spending on US plants. Reuters tallied roughly $500B in announced US investments between January and August 2026, and the leaderboard looks like this: Pfizer $70B; Merck more than $70B; Johnson & Johnson $55B over four years; Roche $50B; AstraZeneca $50B by 2030; Eli Lilly at least $27B for four new sites; Novartis $23B across 10 facilities; Sanofi at least $20B through 2030; AbbVie $100B over a decade. Bayer's $2.2B announcement slots it in the third tier of individual plant commitments — comparable to Bristol Myers Squibb's $2.3B Houston facility, not to Eli Lilly's multi-site buildout.

The site choice says something Bayer doesn't put in the press release. New Albany is the same Ohio International Business Park where Amgen has been compounding for five years — its first 270,000-square-foot assembly and packaging plant went up in 2022, and in April 2025 it announced a $900M expansion adding 350 jobs. The neighboring Intel Ohio One fab (originally $20B, now $1.5B of CHIPS Act funding and a delayed 2030–2032 completion) gives the region a workforce and utility backbone that wouldn't exist without the semiconductor anchor. Bayer is leveraging Amgen's pre-existing footprint and a state-funded $30M Ohio Life Sciences Training Center that opens in summer 2027 — exactly the lead time Bayer needs before its 2031 first-module startup.

Bayer's pharma sales were €17.83B in 2025 (+1.7% currency- and portfolio-adjusted), and the segment's EBITDA before special items of €4.53B is being eaten alive by a brutal franchise rotation: Xarelto off -31.6%, Eylea off -3.7% (with Eylea 8 mg now ~38% of franchise sales), and royalty pressure on the rest. The growth engine is concentrated, and it has to work.

The asundexian number is the load-bearing one. The drug cut recurrent stroke by 26% versus placebo without raising major bleeding in OCEANIC-STROKE — a profile that made it the only late-stage Factor XIa inhibitor still standing after Bristol Myers Squibb's milvexian failed — and a Priority Review puts approval on the calendar before the Ohio plant's first module is even finished. Bayer has guided to peak sales of more than €5B for asundexian; the Ohio site's drug-substance module is sized for exactly that kind of volume ramp. Building a US plant for a drug that hasn't been approved yet is a forward bet, but the safety/efficacy profile and the regulatory calendar make it a calculable one.

Bayer has paid out roughly $11B in Roundup verdicts and settlements since acquiring Monsanto in 2018, and the proposed $7.25B class settlement — declining capped annual payments over up to 21 years — is the mechanism that finally puts the back of the book behind the company. The Missouri circuit court in St. Louis (Judge Timothy Boyer) gave the deal preliminary approval in March 2026 and held the final fairness hearing on September 14, 2026. As of October 2, the ruling has not been issued, but the deal's structure means Bayer is committing to a known, multi-decade cash outflow at the same time it is committing to a $2.2B plant that won't turn on until 2031.

Net debt tells the other side of the same story. Net financial debt stood at €29.84B at year-end 2025 — down 8.5% from 2024 but still multiples of the company's annual free cash flow — and the $7.25B settlement, even stretched over 21 years, sits ahead of the $2.2B Ohio project in the capital queue. The argument for the plant is that protecting three growth drugs (Nubeqa, Kerendia, asundexian) from the new 100% tariff is worth more than the carrying cost of the deferred capex. The argument against is that Bayer is committing to a 200-acre concrete pour on the same balance sheet that just absorbed an €11B litigation bill.

CDMO capacity for oral solid-dose and small-molecule drug substance is not the bottleneck — Catalent, Lonza and a handful of US-based contract manufacturers have plenty of room. The reason to own a US plant comes down to three things the CDMO model can't deliver at the same time: tariff immunity, supply security for asundexian's narrow Factor XIa inhibitor chemistry, and integration with Bayer's existing Whippany, NJ pharma headquarters and the Berkeley, CA cell-therapy facility it opened in October 2023 for $250M. The 200-acre site is also being designed as a digital-and-automation-enabled flexible campus — a hedge against the next portfolio rotation, not just the current one.

The next 12 months will be defined by the Roundup settlement final approval, the asundexian PDUFA decision, and any new tariff agreement Bayer negotiates with the White House. None of those moves the plant itself — but each one moves the balance sheet against which the plant has to earn its keep.

Strip out the press-release language and the Bayer Ohio plant is a single sentence: the company is going to spend $2.2B between now and 2034 to make sure that Nubeqa, Kerendia and asundexian can be sold in the United States without paying the new 100% drug tariff. That is a sensible hedge for a portfolio whose growth is concentrated in exactly three drugs, all of which now face the Section 232 duty on imports from Germany and Finland. It is also a hedge Bayer needed to commit to about three years later than its Annex III-listed competitors, which is why the capex amount is on the small side of the peer set and the timeline is back-loaded.

The risk is execution, not strategy. Bayer is building a 200-acre greenfield in a state it has never manufactured in, on a balance sheet that is still absorbing Roundup payouts, with a return profile that depends on a drug (asundexian) that has not yet been approved. CEO Bill Anderson has been running the turnaround since June 2023, and the pharma-segment EBITDA line is showing the cost of the franchise rotation in real time — H1 2026 pharma EBITDA before special items of €2.30B was down 5.7% year-over-year even as Nubeqa and Kerendia grew 78% and 87% respectively in Q1.

What changes the call: an asundexian approval by year-end 2026 turns the Ohio plant into a near-term capacity decision. A Roundup settlement rejection by Judge Boyer reopens the litigation tail and forces the capex into a different priority queue. A negotiated tariff agreement with the White House — on the Pfizer template — softens the urgency but doesn't kill the project, because Bayer still needs a US site to qualify its supply chain for the next-generation Factor XIa portfolio it is building around asundexian's chemistry.